Personalized medicine (PM) is about developing an individualized approach to each patient's illness. Understanding how a patient's genomic portfolio renders them prone to various diseases may be enhanced by discovering genetic, epigenetic, and medical evidence. Medical therapy that is safe and effective for specific individuals may be predicted using the PM approach, which is a complete expansion of an older methodology (One-Size-Fits-All). Patient’s well-being and longevity may improve and costs are reduced if PM is used. Using existing biomarkers and early genome and epigenomic processes to better understand PM may lead to earlier diagnosis of the disease, including carcinogenesis. A key focus of the PM technique is preventative medicine, which emphasizes proactive actions rather than depending only on reactive ones. More intrusive procedures may be avoided or postponed using this technique, resulting in a higher quality of life and lower financial burdens for patients. End-of-life care costs are putting a strain on governmentfunded healthcare systems across the globe, notably in the United States. When used in conjunction with present treatments, PM may help them work better and lessen the disadvantages of just non-PM methods. Using genetic profiling, doctors may choose a drug based on a participant's genetic profile that minimizes unwanted side effects and ensures a better result while also being less costly than a 'trial-and-error' approach to sickness treatment. The less effective non- PM ('trial-and-error') strategy leads to drug toxicity, severe adverse effects, reactive treatment, and misdiagnosis. PM and proactive therapeutic regimens should be used more often to save costs and enhance overall well-being.
[http://dx.doi.org/10.1097/GIM.0b013e31815699d0] [PMID: 18073579]